# Bladder symptoms and BCG infection after intravesical therapy for non-muscle-invasive bladder cancer

Source: https://onco.cc/protocols/bladder-symptoms-and-infection-after-intravesical-therapy/  
OnCo record `bladder-symptoms-and-infection-after-intravesical-therapy` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Treatments put into the bladder for early bladder cancer, such as BCG, often irritate it: burning, passing urine often or urgently, and some blood in the urine. After BCG this usually settles within 1 to 3 days. Rarely the BCG bacteria cause a serious infection. A high temperature for more than 48 hours, or feeling very unwell, means contacting your doctor immediately.

## Summary

This page sets out what the guidelines and labels read say; a unit's own protocol comes first. Local irritation is expected after BCG: the US TICE BCG label reports bladder irritability in approximately 60% of patients, starting 4 to 6 hours after instillation and lasting 24 to 72 hours, and the UK OncoTICE SmPC says approximately 90% develop local irritative symptoms that in most cases disappear within two days. EAU 2026 lists as absolute contraindications to an instillation the first two weeks after TURBT, visible haematuria, traumatic catheterisation and symptomatic urinary tract infection (Strong). The US label waits 7 to 14 days after biopsy, resection or traumatic catheterisation; the UK SmPC starts 10 to 15 days after resection and delays until mucosal damage has healed.

For cystitis symptoms EAU Table 7.1 (management options, unrated, modified from IBCG) gives phenazopyridine, mirabegron or NSAIDs; if symptoms persist or worsen, postpone the instillation, culture the urine and start empirical antibiotics; then quinolones for a negative culture, and anti-tuberculosis drugs with corticosteroids if symptoms still persist. NICE (England, 2015) says not to offer primary prophylaxis against BCG bladder toxicity outside a trial, and to seek specialist multidisciplinary advice when antispasmodics or non-opiate analgesia fail and cystoscopy has excluded other causes. EAU rates quinolones for BCG side effects Weak ('cautiously offer'). The labels disagree on isoniazid for local symptoms: the US label says antituberculosis drugs should not be used to prevent or treat them, the UK SmPC allows isoniazid 300 mg daily with analgesics for severe symptoms during maintenance.

Fever with malaise generally resolves within 48 hours (EAU). The threshold for suspecting BCG infection differs: above 38.5°C for more than 48 hours (EAU, and the Canadian guideline at 38.5°C or more for 48 hours or more); 38.5°C or more persisting longer than 2 to 3 days, flu-like symptoms beyond 72 hours or 103°F or more (US label); above 39°C not resolving within 12 hours despite antipyretics (UK SmPC). EAU's options are then permanent discontinuation of BCG, immediate evaluation (urine culture, blood tests, chest X-ray), prompt treatment with more than two antimicrobial agents and consultation with an infectious disease specialist; the Canadian guideline suspends BCG until resolved or considers dose reduction and starts at least 2 empirical antimicrobials. For BCG sepsis both list stopping BCG, high-dose quinolones, isoniazid with rifampicin and ethambutol for six months, and high-dose corticosteroids (early in EAU, if persistent in the Canadian guideline); the Canadian guideline says it requires hospitalisation (LE 3, strong recommendation). EAU puts systemic BCG infection at 1 to 2%.

The newer agents' labels give little management. Nadofaragene: anticholinergic premedication is recommended (US and EU); the EU SmPC alone says to exclude urinary tract infection before each instillation and interrupt treatment for one. Gemcitabine intravesical system: prophylactic antibiotics may be used at insertion and removal at the clinician's discretion (US label; urinary tract infection 44%). Nogapendekin alfa with BCG: patients are advised to report prolonged irritable bladder symptoms or prolonged red urine immediately, and BCG's own label applies. The AUA/SUO guideline could not be read.

## Fields

- Kind: Protocol
- Last checked: 2026-11-18
- Also known as: BCG cystitis; BCG side effects; BCG toxicity management; BCG sepsis; BCGosis; systemic BCG infection; bladder irritation after BCG; side effects of bladder instillations; intravesical therapy side effects; bladder spasm after nadofaragene; TAR-200 urinary side effects

## Connected records

- drugs: [Gemcitabine intravesical system (TAR-200)](https://onco.cc/drugs/tar-200/), [Intravesical BCG](https://onco.cc/drugs/bcg-intravesical/), [Levofloxacin](https://onco.cc/drugs/levofloxacin/), [Nadofaragene firadenovec](https://onco.cc/drugs/nadofaragene-firadenovec/), [Nogapendekin alfa inbakicept](https://onco.cc/drugs/nogapendekin-alfa/)
- cancers: [Non-muscle-invasive bladder cancer](https://onco.cc/cancers/non-muscle-invasive-bladder-cancer/)
- terms: [BCG-unresponsive](https://onco.cc/terms/bcg-unresponsive/), [Intravesical therapy (BCG and bladder instillations)](https://onco.cc/terms/intravesical-therapy/), [Transurethral resection of bladder tumour (TURBT)](https://onco.cc/terms/turbt/)
- protocols: [Ifosfamide: bladder protection with mesna and fluids, and ifosfamide encephalopathy](https://onco.cc/protocols/ifosfamide-bladder-protection-and-encephalopathy/)

---
JSON: https://onco.cc/api/v1/entities/bladder-symptoms-and-infection-after-intravesical-therapy.json